New Improved Dosing Approved for Pennsaid
MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ -- Nuvo Research
Inc. (TSX: NRI), a Canadian drug development company focused on the
research and development of drug products delivered to and through
the skin using its topical and transdermal drug delivery
technologies, and Paladin Labs Inc. (TSX: PLB), a leading Canadian
specialty pharmaceutical company, today announced that Health
Canada has approved a new dosing regimen for Pennsaid(R) (topical
diclofenac). Paladin sells and markets Pennsaid in Canada, having
acquired exclusive Canadian Pennsaid rights from Nuvo in August
2005.
The new dosing regimen of Pennsaid(R) will be 50 drops per knee,
3 times a day, as an alternative to the existing approved dosing
regimen of 40 drops per knee, 4 times a day. Pennsaid(R) is now the
only topical NSAID approved in Canada with this new improved dosing
regimen. Pennsaid had Canadian sales of $10.6 million last year and
has been sold in Canada since May 2003.
"Pennsaid(R) is a proven effective treatment for Osteoarthritis
of the knee," said Dr. Philip Baer, a Rheumatologist practicing in
Ontario. "The newly approved dosing regimen of 50 drops TID
(three-times-per-day) will make it easier for patients to use
Pennsaid(R) to manage their pain, as compared to applying 40 drops
QID (four-times-per-day). TID dosing can improve patient
compliance, which is one of the most important factors in ensuring
effective pain relief."
"The new improved dosing regimen of Pennsaid(R) is a significant
clinical advantage," said Henrich Guntermann, Nuvo's President and
CEO. "We are eager to replicate Pennsaid's Canadian success in the
U.S. market and continue to work diligently on obtaining U.S. FDA
approval."
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a
leading specialty pharmaceutical company focused on developing,
acquiring or in-licensing innovative pharmaceutical products for
the Canadian market. With this strategy, a focused national sales
team and proven marketing expertise, Paladin has evolved into one
of Canada's leading specialty pharmaceutical companies. Paladin's
shares trade on the Toronto Stock Exchange under the symbol PLB.
For more information about Paladin, please visit the Paladin web
site at www.paladinlabs.com.
About Nuvo Research Inc.
Nuvo is focused on the research and development of drug products
delivered to and through the skin using its topical and transdermal
drug delivery technologies. Nuvo's lead product is Pennsaid(R), a
topical non-steroidal anti-inflammatory (NSAID) used for the
treatment of osteoarthritis. Nuvo intends to leverage its
skin-penetrating technologies to create a portfolio of topical and
transdermal products targeting a variety of indications.
Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical
company headquartered in Mississauga, Ontario, with manufacturing
facilities in Varennes, Quebec and Wanzleben, Germany and a
research and development Center in San Diego California. For more
information, please visit www.nuvoresearch.com.
This release may contain forward-looking statements, subject to
risks and uncertainties beyond management's control. Actual results
could differ materially from those expressed here. Risk factors are
discussed in the Companies' annual information forms filed with the
securities commissions in each of the provinces of Canada. The
Companies referred to herein undertake no obligation to revise
forward-looking statements in light of future events.
Source: Nuvo Research Inc.
CONTACT: about Paladin, please contact: Samira Sakhia, Chief
Financial
Officer, Paladin Labs Inc., Tel: (514) 340-5067, email: info@paladin-labs.com;
For more information about Nuvo, please contact: Investor
Relations, Christina
Bessant, Equicom Group Inc., Tel: (416) 815-0700 x269, email:
cbessant@equicomgroup.com
Posted: June 2008
